Clincosm LogoSign in Get a demo

Arizona Alzheimer's Disease Research Center (ADRC)

Sponsor
Banner Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT05405075
Collaborator
(none)
550
Enrollment
1
Location
56.9
Anticipated Duration (Months)
9.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United States, and a leading example of statewide collaboration in biomedical research. It capitalizes on Arizona's strengths in brain imaging, genomics, computer science and biomathematics, the basic, cognitive and behavioral neurosciences, clinical, and neuropathological studies of AD, the discovery and evaluation of investigational treatments, and the study of normal cognitive aging.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    550 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Arizona Alzheimer's Disease Research Center (ADRC)
    Actual Study Start Date :
    Oct 1, 2021
    Anticipated Primary Completion Date :
    Jun 30, 2026
    Anticipated Study Completion Date :
    Jun 30, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Cognitive Status [12 months]

      The ADRC uses a prospective, standardized, and longitudinal clinical evaluation of participants to determine their cognitive status. This includes tests that assess short and long term memory, ability to complete daily tasks, and processing of information.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Cognitively normal persons, individuals with mild cognitive impairment or dementia who are at least 40 years of age.

    • Willing to undergo health and cognitive assessments, and collection and banking of blood with venipuncture for genetic research, biomarker research, and DNA banking.

    Exclusion Criteria:
      1. Participants whose diagnosis is unclear and confounded by multiple possible factors are excluded. Participants with diagnoses of non-AD dementias are not excluded.

    1. Participants whose primary diagnosis is cognitive impairment due to a penetrating or single severe closed head injury, multiple sclerosis, brain tumor, metabolic or toxic encephalopathy, post-infectious (e.g., viral encephalitis, bacterial meningitis), paraneoplastic, primary psychiatric illness, or otherwise not deemed relevant to the intent of the Alzheimer Disease Center program are excluded.

    2. Procedure specific exclusion criteria also apply but this does not impact the participants ability to be included in the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Banner Alzheimer's Institute Phoenix Arizona United States 85006

    Sponsors and Collaborators

    • Banner Health

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Banner Health
    ClinicalTrials.gov Identifier:
    NCT05405075
    Other Study ID Numbers:
    • ADRC-001
    First Posted:
    Jun 6, 2022
    Last Update Posted:
    Jun 6, 2022
    Last Verified:
    Jun 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Alzheimer Disease

    Study Results

    No Results Posted as of Jun 6, 2022